View Exam | PowerPak

1. An increase in which of the following is a main contributor to the disordered iron homeostasis and anemia of chronic kidney disease (CKD) by impairing dietary iron absorption and iron mobilization from body stores?

A. Erythropoietin B. Ferroportin C. Hepcidin D. Transferrin

2. Which of the following is true regarding the mechanism of action of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors?

A. They enhance the degradation of HIF-α, resulting in enhanced erythropoietic gene transcription B. They bind to erythropoietin receptors and stimulate erythropoiesis C. They bind to hepcidin receptors and inhibit its interaction with ferroportin D. They stabilize the HIF complex and stimulate endogenous erythropoietin production

3. Which of the following describes the results seen in current clinical trials for different HIF-PH inhibitors in development?

A. No change in hemoglobin (Hb) and reduced hepcidin levels B. Increased Hb and increased hepcidin levels C. Increased Hb and no change in hepcidin levels D. Increased Hb and reduced hepcidin levels

4. Based on available results from phase 3 clinical trials demonstrating superiority over placebo, treatment with which of the following would likely significantly improve Hb levels in a patient with nondialysis-dependent (NDD)–CKD and anemia?

A. Daprodustat B. Molidustat C. Roxadustat D. Vadadustat

5. Which of the following most accurately describes recently reported findings from pooled analyses of the roxadustat global phase 3 program looking at cardiovascular safety?

A. In incident dialysis patients, roxadustat had a lower risk of major adverse cardiovascular events (MACE) and MACE+ and showed a trend toward lower risk of all-cause mortality relative to epoetin alfa B. Dialysis-dependent patients receiving roxadustat had a higher risk of MACE+ and increased risk of MACE or all-cause mortality versus epoetin alfa C. In NDD patients receiving roxadustat, the risk of MACE, MACE+, and all-cause mortality was higher than placebo D. In all patients receiving roxadustat (NDD; incident dialysis; dialysis-dependent), the risk of MACE, MACE+, and all-cause mortality was comparable with placebo or epoetin alfa

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. An increase in which of the following is a main contributor to the disordered iron homeostasis and anemia of chronic kidney disease (CKD) by impairing dietary iron absorption and iron mobilization from body stores?

2. Which of the following is true regarding the mechanism of action of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors?

3. Which of the following describes the results seen in current clinical trials for different HIF-PH inhibitors in development?

4. Based on available results from phase 3 clinical trials demonstrating superiority over placebo, treatment with which of the following would likely significantly improve Hb levels in a patient with nondialysis-dependent (NDD)–CKD and anemia?

5. Which of the following most accurately describes recently reported findings from pooled analyses of the roxadustat global phase 3 program looking at cardiovascular safety?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. An increase in which of the following is a main contributor to the disordered iron homeostasis and anemia of chronic kidney disease (CKD) by impairing dietary iron absorption and iron mobilization from body stores?

2. Which of the following is true regarding the mechanism of action of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors?

3. Which of the following describes the results seen in current clinical trials for different HIF-PH inhibitors in development?

4. Based on available results from phase 3 clinical trials demonstrating superiority over placebo, treatment with which of the following would likely significantly improve Hb levels in a patient with nondialysis-dependent (NDD)–CKD and anemia?

5. Which of the following most accurately describes recently reported findings from pooled analyses of the roxadustat global phase 3 program looking at cardiovascular safety?

« Return to Activity

Customers who Purchased
this Activity also Purchased